Comparative Pharmacology
Head-to-head clinical analysis: ARBLI versus CEFAZOLIN IN DEXTROSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARBLI versus CEFAZOLIN IN DEXTROSE.
ARBLI vs CEFAZOLIN IN DEXTROSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARBLI (arbaclofen placarbil) is a prodrug of baclofen, a GABA-B receptor agonist. It acts presynaptically to inhibit excitatory neurotransmitter release and postsynaptically to reduce neuronal excitability, leading to muscle relaxation.
Cefazolin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby disrupting peptidoglycan cross-linking.
10 mg orally once daily.
1-2 g IV every 8 hours. For serious infections, up to 2 g IV every 6 hours.
None Documented
None Documented
Terminal elimination half-life of 26 hours (range 20-32 h), supporting once-daily dosing; prolonged in hepatic impairment.
1.8 hours in normal renal function. Prolonged to 12-24 hours in end-stage renal disease (CrCl <10 mL/min).
Primarily biliary (>70%) and fecal elimination; renal excretion accounts for <5% of unchanged drug.
Renal: 80-90% unchanged by glomerular filtration and tubular secretion. Biliary: minor (<1%). Fecal: negligible.
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic